The high mortality of ovarian cancer (OvCa) is caused by the wide dissemination of cancer cells within the abdominal cavity, which results in significant tumor burden. The first cells which metastatic OvCa cells encounter are the mesothelial cells which line the peritoneum and omentum of the abdominal cavity. We established an organotypic 3D culture of the peritoneum and omentum using primary human fibroblasts, mesothelial, and OvCa cells that allowed us to mimic the early steps of metastasis in a cell culture. Following the attachment of OvCa cells to the peritoneum, cancer cell derived MMP-2 cleaves fibronectin into smaller pieces which promotes ????-integrin mediated adhesion and metastasis. c-Met supports the metastasis of OvCa cells through its physical with ????- integrin, which allows the HGF-independent activation of c-Met/Src/Fak intracellular signaling. Additional mechanisms which promote OvCa dissemination involve the interaction of ????-integrin with the urokinase receptor (uPAR) Most of the results obtained during the previous funding period point towards a prominent role for the ????-integrin - fibronectin interaction in ovarian cancer metastasis. This is also supported by our clinical studies, which established that 90% of all OvCa metastases express fibronectin in the stroma. Because our preliminary data suggest that mesothelial cells are the source of fibronectin, the primary hypothesis underlying this application is that OvCa cells stimulate human mesothelial cells to secrete fibronectin, which increases OvCa invasion and metastasis.
In Aim I we will elucidate the mechanisms with which the interaction of mesothelial cells with OvCa cells promotes invasion and metastasis through secretion of fibronectin. Experiments will include studying the role of fibronectin in vivo using a floxed fibronectin knock-out mouse which allows deletion of fibronectin in mesothelial cells, analysis of fibronectin promoter regulation in mesothelial cells, and a siRNA screen to understand how OvCa cells promote fibronectin secretion in the mesothelial cells.
In Aim II we will perform a detailed study to identify which fibronectin fragments promote the association between ????-integrin and c-Met. This will be followed by deletion of functional domains in ??-integrin and c-Met to define the binding sites where the two proteins interact and the biological significance of this protein-protein interaction for the intra cellular signaling, invasion, and metastasis of OvCa cells. Based on the findings in Aims I and II, in Aim III, we will combine a c-Met inhibitor with a fibronectin peptide known to block the effect of fibronectin binding integrins and test them in pre-clinical treatment studies using an orthotopi xenograft model (bursal injection of primary cells) as well as in a genetic model of OvCa. Successful inhibition of fibronectin function could result in a novel and clinically relevant approach to the treatment of metastatic ovarian cancer.

Public Health Relevance

The biology of ovarian cancer metastasis is still poorly understood and, therefore, minimal progress has been made in its treatment. Our findings, that the mesothelial cells lining the abdominal cavity promote ovarian cancer metastasis through the secretion of fibronectin, have led us to examine how the interaction between fibronectin and its receptor, ????-integrin, promotes tumor growth and metastasis. Studies will include pre-clinical testing of compounds that inhibit this interaction, with the goal of translating the knowledge gained into new treatments for this devastating disease.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA111882-07
Application #
8534033
Study Section
Tumor Microenvironment Study Section (TME)
Program Officer
Sathyamoorthy, Neeraja
Project Start
2004-12-01
Project End
2017-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
7
Fiscal Year
2013
Total Cost
$255,979
Indirect Cost
$93,967
Name
University of Chicago
Department
Obstetrics & Gynecology
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Lengyel, Ernst; Litchfield, Lacey M; Mitra, Anirban K et al. (2015) Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models. Am J Obstet Gynecol 212:479.e1-479.e10
Febbraro, Terri; Lengyel, Ernst; Romero, Iris L (2014) Old drug, new trick: repurposing metformin for gynecologic cancers? Gynecol Oncol 135:614-21
Habis, Mohammed; Wroblewski, Kristen; Bradaric, Michael et al. (2014) Statin therapy is associated with improved survival in patients with non-serous-papillary epithelial ovarian cancer: a retrospective cohort analysis. PLoS One 9:e104521
Ko, Song Yi; Ladanyi, Andras; Lengyel, Ernst et al. (2014) Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am J Pathol 184:271-81
Kenny, Hilary A; Chiang, Chun-Yi; White, Erin A et al. (2014) Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion. J Clin Invest 124:4614-28
Nieman, Kristin M; Romero, Iris L; Van Houten, Bennett et al. (2013) Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 1831:1533-41
Lengyel, Ernst; Fleming, Saroj; McEwen, Kelsey A et al. (2013) Serial sectioning of the fallopian tube allows for improved identification of primary fallopian tube carcinoma. Gynecol Oncol 129:120-3
Boyerinas, Benjamin; Park, Sun-Mi; Murmann, Andrea E et al. (2012) Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1. Int J Cancer 130:1787-97
Romero, Iris L; Lee, WooSeok; Mitra, Anirban K et al. (2012) The effects of 17?-estradiol and a selective estrogen receptor modulator, bazedoxifene, on ovarian carcinogenesis. Gynecol Oncol 124:134-41
Romero, Iris L; McCormick, Anna; McEwen, Kelsey A et al. (2012) Relationship of type II diabetes and metformin use to ovarian cancer progression, survival, and chemosensitivity. Obstet Gynecol 119:61-7

Showing the most recent 10 out of 30 publications